Pyrazolobenzotriazinone derivatives as COX inhibitors: Synthesis, biological activity, and molecular-modeling studies

Archiv der Pharmazie

Volumn 343, Issue 11-12, 2010, Pages 631-638

  Raffa, Demetrio ^a   Migliara, Onofrio ^a   Maggio, Benedetta ^a   Plescia, Fabiana ^a   Cascioferro, Stella ^a   Cusimano, Maria Grazia ^a   Tringali, Giuseppe ^b   Cannizzaro, Carla ^a   Plescia, Fulvio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

2 (1H Pyrazol 1 yl) pyridines; 4(3H) Benzotriazinones; COX 2 inhibitors; Docking

Indexed keywords

5 (4 OXO 1,2,3 BENZOTRIAZIN 3(4H) YL) 1 PYRIDIN 2 YL 1H PYRAZOLE 4 CARBOXYLIC ACID; 5 (6 CHLORO 4 OXO 1,2,3 BENZOTRIAZIN 3(4H) YL) 1 PYRIDIN 2 YL 1H PYRAZOLE 4 CARBOXYLIC ACID; 5 (7 CHLORO 4 OXO 1,2,3 BENZOTRIAZIN 3(4H) YL) 1 PYRIDIN 2 YL 1H PYRAZOLE 4 CARBOXYLIC ACID; ACETIC ACID; CYCLOOXYGENASE 2 INHIBITOR; ETHYL 5 (4 OXO 1,2,3 BENZOTRIAZIN 3(4H) YL) 1 PYRIDIN 2 YL 1H PYRAZOLE 4 CARBOXYLATE; ETHYL 5 (6 CHLORO 4 OXO 1,2,3 BENZOTRIAZIN 3(4H) YL) 1 PYRIDIN 2 YL 1H PYRAZOLE 4 CARBOXYLATE; ETHYL 5 (7 CHLORO 4 OXO 1,2,3 BENZOTRIAZIN 3(4H) YL) 1 PYRIDIN 2 YL 1H PYRAZOLE 4 CARBOXYLATE; PYRAZOLOBENZOTRIAZINONE; SODIUM NITRITE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; MOLECULAR MODEL; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; MODELS, MOLECULAR; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRIAZINES;

EID: 78649817084     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200900317     Document Type: Article

References (17)

1. R. G. Kurumbail, J. R. Kiefer, L. J. Marnett, Curr. Opin. Struc. Biol. 2001, 11, 752-760.
2. D. L. Simmons, R. M. Botting, T. Hla, Pharmacol. Rev. 2004, 56, 387-437.
3. M. Gupta, G. M. Glenn, Curr. Gastroenterol. Rep. 2009, 32, 25-32.
4. B. M. Peskar, J. Physiol. 2001, 3-9.
5. M. Lazzaroni, A. Battocchia, G. Bianchi Porro, Dig. Liver Dis. 2007, 39, 589-596.
6. M. D. Loren Laine, Semin. Arthritis Reum. 2002, 32, 25-32.
7. C. Blandizzi, M. Tuccori, R. Colucci, M. Fornai, et al,., Pharmacol. Res. 2009, 59, 90-100.
8. S. Plescia, D. Raffa, G. Daidone, B. Maggio, Il Farmaco 1994, 49, 505-507.
9. G. Daidone, S. Plescia, D. Raffa, M. L. Bajardi, et al,., Il Farmaco 1990, 45, 391-398.
10. G. Daidone, B. Maggio, S. Plescia, D. Raffa, et al,., Il Farmaco 1998, 53, 350-356.
11. R. G. Kurumbail, A. M. Stevens, J. K. Gierse, J. J. McDonald, et al,., Nature 1996, 384, 644-648.
12. K. Gupta, B. S. Selinsky, C. J. Kaub, A. K. Katz, P. J. Loll, J. Mol. Biol. 2004, 335, 503-518.
13. A. Andreani, M. Granaioloa, A. Leoni, A. Locatelli, et al,., Eur. J. Med. Chem. 2004, 39, 785-791.
14. J. A. Mancini, D. Riendeau, J. P. Falgueyret, P. J. Vickers, G. P. O'Neill, J. Biol. Chem. 1995, 270, 29372-29377.
15. M. L. Plount Price, L. Jorgensen, J. Am. Chem. Soc. 2000, 122, 9455-9466.
16. G. Pozzoli, G. Tringali, C. Dello Russo, M. Vairano, et al,., J. Neuroimmunol. 2001, 118, 268-276.
17. G. Tringali, G. Pozzoli, M. Vairano, N. Mores, et al,., J. Neuroimmunol. 2005, 160, 61-67.